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journal homepage: www.elsevier.com/locate/ihjCardiovascular disease burden rises with increasing age and it
remains the leading cause of morbidity and mortality in the
elderly. In the United States (U.S.), roughly one-third of deaths
in the elderly each year can be attributed to acute coronary
syndromes (ACS).1 However, clinical trial populations have
traditionally been fraught with the problem of inadequate
depiction of the 'real-world' demographics of ACS patients.
The proportional representation of elderly patients in ACS
clinical trials is much lower (10%) than that seen in everyday
clinical practice, where around 35% of ACS patients are aged
≥75 years.2 Since data from trials exclusively enrolling elderly
patients are scarce, the current management of elderly patients
with ACS is essentially dictated by subgroup analyses from
major ACS trials. This evidence does demonstrate the
effectiveness of both timely coronary reperfusion and second-
ary prevention medications (such as beta-blockers, statins, and
angiotensin-converting enzyme (ACE) inhibitors/aldosterone II
receptor blockers (ARBs)) even in the oldest group of patients.3
However, multiple studies have shown that the elderly are
much less likely than the younger patients to receive these ACS
therapies.4 Moreover, community elderly patients with ACS are
sicker and more likely to have hypertension, prior stroke, acute
heart failure, cardiogenic shock, and atrioventricular block
(AVB) than trial patients. Therefore, there is a dire need of real-
world clinical data on the presenting characteristics, receipt of
treatment strategies, and outcomes in the elderly patients with
ACS, as well as temporal changes in these parameters.
In this issue of the Indian Heart Journal, Jomaa et al.5 examine
the differences in baseline clinical characteristics, rates of
reperfusion therapy, and in-hospital outcomes in elderly
patients aged ≥75 years (n = 211; 15%) vs. those aged <75
years (n = 1192; 85%) in a cohort of 1403 patients presenting
with ST-elevation myocardial infarction (STEMI) to a Tunisian
University hospital over a 16-year period from 1998 to 2013.
Elderly patients were less likely to be women and more likely
to be hypertensive and anemic. The prevalence of smoking
and obesity was lower in the elderly group. Fibrinolytic therapy
(22.3% vs. 36.6%, p < 0.001) and primary percutaneous coro-
nary intervention (pPCI; 24.2% vs. 28.8%, p = 0.17) were less
frequently utilized, whereas conservative medical therapywas more common in the elderly (43.1% vs. 28.9%, p < 0.001).
Interestingly, there were no statistically signiﬁcant differences
in the time from symptom onset to reperfusion (either by
thrombolysis or pPCI) in elderly vs. younger STEMI patients. As
would be expected, complications such as heart failure and
renal failure on admission, new onset atrial ﬁbrillation, AVB,
cardiogenic shock, and use of inotropes were more common in
the elderly. Also, in-hospital mortality in the elderly was
almost two-fold in comparison to the younger cohort (14.2%
vs. 8.1%, p = 0.005). On multivariate analysis, heart failure on-
admission, renal failure on-admission, and use of inotropic
therapy were found to be independent predictors of in-
hospital mortality. The authors also investigated the temporal
trends in use of ﬁbrinolytic therapy and pPCI as well as in-
hospital mortality in both the elderly and younger age groups.
Overall, although the use of both reperfusion strategies
increased over the study period in both age groups, it remained
lower in the elderly throughout. Intriguingly, there was a
substantial increase in crude in-hospital mortality in both
younger and elderly patients with STEMI over the study years,
but the authors did not perform univariate or multivariate
analysis to study the statistical signiﬁcance of this trend.
There are several important points to consider while
interpreting this study's ﬁndings. First, as pointed out by
the authors themselves, their study population represents a
largely urban cohort of patients with relatively westernized
lifestyles and with ready access to modern STEMI systems of
care, including trained emergency medical services (EMS) and
pPCI facilities. Therefore, these results cannot be generalized
to the broader Tunisian or North African populations, where a
signiﬁcant section of the population is still predominantly
rural. This assumption is reinforced by this study's ﬁnding of
no signiﬁcant differences in the time from symptom onset to
reperfusion in elderly vs. younger patients, whereas studies
even in the U.S. setting have shown older age to be a predictor
of longer pre-hospital delays.3 Moreover, none of the patients
in the current study were transfers from primary or secondary
level of care healthcare facilities and all patients were brought
directly to the emergency department of the University
hospital by EMS services with a conﬁrmed electrocardiograph-
ic (ECG) diagnosis of STEMI. It is well known that initial
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pPCI capabilities is associated with reperfusion delays due to
both delayed recognition of STEMI and then the time needed
for inter-hospital transfer, leading to worse short- and long-
term outcomes. It is probable that the majority of the North
African patients do not have access to these organized systems
of care and indeed have much worse outcomes than that
reported in this study.
The proportion of elderly STEMI patients (15%) in this study
was lower than that what has been observed in the Western
literature. Large multi-center U.S. ACS registries, such as the
Global Registry of Acute Coronary Events (GRACE) and National
Registry of Myocardial Infarction (NRMI), have reported the
prevalence of elderly patients aged over 75 years to be around
30% in contemporary STEMI cohorts.3 Whether the demo-
graphics of STEMI patients is different between Tunisian and
the Western populations in general, or the lower proportion of
elderly patients in this study represents some sort of a selection
bias, will need to be established by future investigations.
The under-utilization of reperfusion in the elderly patients
when compared with younger patients is consistent with
results from several U.S. studies.6 The current U.S. STEMI
guidelines recommend treatment with reperfusion for patients
presenting within 12 h of symptom onset in the absence of
contraindications.7 However, the proportion of STEMI patients
eligible for reperfusion therapy decreases with age. Common
reasons for elderly being ineligible for reperfusion therapy with
ﬁbrinolysis or pPCI include delayed presentation several hours
after symptom onset, abnormal ECG at baseline, atypical ECG
ﬁndings, and frequent absence of chest pain as a presenting
symptom leading to a diminished suspicion for STEMI at the
point of initial medical contact. Also, elderly are more likely to
have both absolute (e.g. uncontrolled hypertension, recent
stroke, history of intracranial hemorrhage, etc.) and relative (e.g.
prior stroke, dementia, chronic anticoagulation) contraindica-
tions to ﬁbrinolytic therapy. Moreover, ﬁndings from the GRACE
registry show that an age ≥75 years is an independent predictor
of failure to receive reperfusion therapy even in eligible
patients.8 Coexisting age-related frailty, high prevalence of
comorbid conditions, frequent cognitive impairment, and
patient preference are some of the reasons that potentially
contribute to lower reperfusion rates in the reperfusion-eligible
elderly patients.3 Additionally, there is often the factor of
‘‘ageism’’, i.e. physician perception of lack of beneﬁt from the
use of an aggressive approach to treat STEMI in elderly patients,
given the overall poor short- and long-term outcomes irrespec-
tive of the treatment strategy. Whether this represents
reasoned clinical judgment or there is an element of therapeutic
nihilism to this approach, remains a frequent matter of medical
debate. Results from the British Myocardial Infarction National
Audit Project (MINAP) show that the elderly are less likely to be
even under the care of a cardiologist during their ACS
hospitalization.4 This, combined with the ﬁndings that older
ACS patients are also less likely to receive proven medical
therapies such as aspirin, beta-blockers, statins, ACE inhibitors/
ARBs both during hospital admission and at discharge, does
suggest that there is a component of nihilism to this practice of
under-treatment in the elderly.3
The optimal modality of reperfusion for STEMI in the
elderly is another conundrum. General consensus agrees thateligible older STEMI patients who receive reperfusion have more
favorable outcomes than those who do not; limited data
available in this population suggest that PCI may be more
favorable over ﬁbrinolytic therapy, especially among patients
presenting more than 3–6 h after symptom onset, which is often
the case in elderly patients. The major beneﬁt of PCI over
ﬁbrinolysis appears to be from reductions in recurrent MIs and
need for target-vessel revascularization with mortality beneﬁts
being more modest.3 In the current study, 24.2% and 22.3% of the
elderly patients over the age of 75 years with STEMI received
reperfusion with ﬁbrinolysis and pPCI, respectively. These rates
are still much lower than contemporary reperfusion rates in the
Western cohorts of elderly STEMI patients, where the reperfu-
sion rates are in the 50–60% range (especially considering that
this study's population does represent a somewhat selected
cohort of patients presenting directly to a tertiary care teaching
facility).3,4 A surprising ﬁnding of the current study is the time
trend in use of reperfusion. From 1998–2001 to 2006–2009,
consistent with worldwide trends, use of thrombolysis de-
creased and pPCI increased in both younger and older patients.
However, from 2006–2009 to 2010–2013, there was a prominent
increase in thrombolysis rates accompanied with a decline in
pPCI rates in both younger and older patients. Whether this
trend was driven by a change in hospital practices or some other
factors, has not been adequately discussed by the authors.
Consistent with results from the Western literature, in-
hospital mortality among elderly with STEMI was almost two-
fold higher than in the younger patients. Mortality rates with
STEMI are known to increase with increasing age mainly due
to more frequent occurrence of mechanical and electrical
complications, such as heart failure, cardiogenic shock, high-
degree AVB, and malignant ventricular arrhythmias.3 The in-
hospital mortality (14.2%) in this study though is actually quite
comparable to that reported in contemporary Western
reports.9 The surprising ﬁnding here again is the temporal
trend in in-hospital mortality. There was a noticeable increase
in in-hospital mortality from 4.7% to 9.8% in the younger group
and from 8.9% to 13% in the elderly from the early to late study
years. This is in stark contrast to the Western literature where
multiple studies have demonstrated a steady decline in in-
hospital mortality after STEMI over the past couple of decades,
especially among the elderly population.9,10 The author's
explanation of this ﬁnding being due to differences in pPCI
programs between Western countries and Tunisia is not
convincing since their data come from a single tertiary-care
center and it is unlikely that there were major system-based
changes within the institution over the study period. It would
have been useful if the authors further explored the reasons
behind this puzzling trend. Whether this was due to an
increase in prevalence of comorbidities among STEMI patients
over the study years? Were there changes in time to
reperfusion over the years?
Lastly, the independent predictors of in-hospital mortality
as deﬁned in this study might not be all-inclusive. Though it is
undeniable that acute heart failure, acute renal failure, and the
need for inotropy predict mortality in STEMI patients, it is
perplexing that well-known positive (thrombolysis, pPCI) and
negative (female sex, diabetes, atrial ﬁbrillation, AVB, reperfu-
sion delays, cardiogenic shock) prognostic factors did not
predict in-hospital mortality in this cohort of elderly patients
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predict mortality in elderly patients with STEMI? Or that
thrombolysis and pPCI are not associated with a mortality
beneﬁt? The likely reason for this is the relative low sample
size (n = 211) of the elderly STEMI population and therefore,
inadequate power to accurately identify all the independent
predictors of in-hospital mortality.
Despite these potential shortcomings, the investigators
should be commended for conducting this important study.
The ﬁndings of this study add greatly to our knowledge about
the practice patterns in management and outcomes of STEMI
in the elderly in the North African continent, from where
published data in the English literature are extremely limited.
Since randomized trials solely enrolling elderly patients with
STEMI are unlikely – given the ethical considerations in
randomizing elderly contemporary STEMI patients to reperfu-
sion vs. conservative management – registry analyses, such as
this, are important to further our understanding of ACS
management practices in this vulnerable population.
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